跳至主要内容
临床试验/DRKS00017081
DRKS00017081招募中4 期

Influence of antibiotics on microbiota, immune response and incidence of ventilator-associated infections - AMIII

Charité Universitätsmedizin Berlin0 个研究点目标入组 40 人开始时间: 2019年5月6日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • patients informed consent;
  • age = 18 years;
  • negative result of pregnancy test in women of childbearing potential (WOCBP); no participation in other clinical trials 30 days prior and after on the day of enrolment;
  • at least intermittendly mechanical ventilation via tracheostomy on the day of enrolment, hospitalization at Charité University hospital for at least 24hrs;
  • state of clinical stability or state of clinical improvement with very high likelihood of development of a state of clinical stability
  • =90 no antibiotic therapy
  • on the day of inclusion completed course of antibiotic therapy that fulfills all of the following criteria:
  • 7-10 days of antibiotic therapy with antimicrobial activity against Gram-negative, Gram-positive and anaerobic bacteria
  • Treatment according to marketing authorisation
  • Treatment according to SmPC
  • Treatment with trade product holding a marketing authorisation in original package
  • Treatment ended 24-72h before inclusion
  • Treatment with at least one of the following active substances (alphabetic order, same order as in Modul 1)
  • Amoxicillin/Clavulansäure p.o.
  • Ampicillin/Sulbactam i.v.
  • Cefazolin i.v.
  • Cefepim i.v.
  • Ceftazidim i.v.
  • Ceftazidim/Avibactam i.v.
  • Ceftolozan/Tazobactam i.v.
  • Ceftriaxon i.v.
  • Ciprofloxacin p.o. oder i.v.
  • Clarithromycin p.o. oder i.v.
  • Clindamycin p.o. oder i.v.
  • Daptomycin i.v.
  • Ertapenem i.v.
  • Flucloxacillin i.v.
  • Gentamicin i.v.
  • Imipenem i.v.
  • Linezolid p.o. und i.v.
  • Meropenem i.v.
  • Metronidazol p.o. oder i.v.
  • Piperacillin/Tazobactam i.v.
  • Tobramycin i.v.
  • Trimethoprim/ Sulfamethoxazol (Cotrimoxazol) p.o. und i.v.
  • Vancomycin i.v.

排除标准

  • pregnancy and breastfeeding
  • instable clinical Situation
  • use of IMP not according to SmPC
  • active pneumonia, that is not fully treated on day of inclusion current acute exacerbation of Asthma bronchiale or COPD
  • confirmed diagnosis on day of enrolment of congenital or acquired
  • immune deficiency
  • current immunosuppressive therapy and/or = 3 months prior to enrolment (in case of corticosteroids = 20mg prednisolone/d or equivalent)
  • current chemotherapy and/or = 3 months prior to enrolment
  • confirmed diagnosis or high clinical suspicion of hematological malignancy including myelodisplastic syndrome, chronic lymphocytic
  • leukaemia or multiple myeloma
  • Crohn's disease or ulcerative colitis
  • confirmed diagnosis of Clostridium difficile Enteritis
  • confirmed diagnosis on day of enrolment of cystic fibrosis
  • confirmed diagnosis on day of enrolment of open lung tuberculosis
  • confirmed diagnosis on day of enrolment of advanced stage lung cancer (stage III/IV)
  • middle or high risk of bronchoscopy as judged by investigating physician
  • all contraindications against medication or adjuvants used for analdosedation during bronchoscopy, in detail against midazolam:
  • hypersensitivity against midazolam
  • acute respiratory failure
  • against propofol:
  • hypersensitivity against propofol or one of the adjuvants, such as soy allergy
  • against lidocain:
  • hypersensitivity against lidocain
  • acute heart failure
  • severe uncontrolled cardiac arrythmia
  • missing consent for storage and transfer of data within the clinical study
  • participation in another clinical trial within 30 days prior or currently
  • previous participation in this study
  • hospitalisation ordered by court

研究者

相似试验

Influence of antibiotics on microbiota, immune... | 临床试验